Tremelimumab for fallopian tube neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 29 Jul 2019: Trial registered, NCT04034927
  2. 4 Dec 2019: Trial started, NCT04034927

The trials

NCT04034927: Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

State
Under way
Phase
Phase 2
People
61 taking part
Started
4 Dec 2019
Primary completion
31 Jul 2021
Arms
Arm II (olaparib, tremelimumab)
Results
Posted on the registry
  1. 29 Jul 2019: Trial registered
  2. 4 Dec 2019: Trial started
  3. 13 Oct 2023: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.